DESCRIPTION

Toxicology as a multidisciplinary, data-rich field has witnessed the availability of a cutting-edge technologies to investigate mechanisms underlying adverse consequences of exposures to xenobiotic chemicals, particularly as it relates to human health. Toxicology fully embraces these advancements by serving as a hub for exchange of information regarding state-of-the-art developments in the broad field of contemporary toxicology. Journal scope emphasis is on human-relevant and mechanistic research at all levels of biological organization, ranging from the molecular scale to the organismal level. The publication priority for Toxicology is on original high-quality research and review papers on any topic relevant to toxicology, in particular related to hazard identification, all that are subject to rigorous peer-review. The Toxicology target audience includes undergraduates to full professionals in academic, industrial and regulatory settings in any part of the world.

Notes from the Editors

In order to support interpretation of published findings to human health, the journal requires inclusion of specific statements within the ABSTRACT and METHODS sections of each submitted article:

ABSTRACT: The experimental system (e.g., in vivo species, cell culture, etc.) including the exposure dose or concentration and duration that produces an effect, if an effect is observed, must be described in the ABSTRACT to the manuscript.MATERIALS AND METHODS: The relevance of the experimental system and exposure dose or concentration and duration in terms of potential human exposures must be described in the Materials and Methods section of the manuscript. Justification of the exposure cannot be based solely on previous publications, but rather the comparison must be to either estimated, anticipated, or measured human exposures. The authors must identify the chemicals by CAS number, their source and purity; the method of randomization for group sampling, the number of experimental sample replicates in each treatment group, and provide a proper description of the statistical analysis of data that was employed. Journal Policy: TOXICOLOGY does not publish results from exposures to uncharacterized chemical mixtures or extracts from natural products. All exposures must be fully characterized analytically. Justification for this policy is that it is near impossible for other investigators to replicate findings of a study wherein the chemical composition of the exposure is not completely characterized. TOXICOLOGY does not publish purely descriptive safety studies or studies describing the therapeutic efficacy of cytotoxic agents without strong emphasis on end-points relating to a proposed mechanism of toxicity.
AUDIENCE

Toxicologists, Pharmacologists, Epidemiologists, Teratologists.

ABSTRACTING AND INDEXING

Pascal Francis
EMBiology
BIOSIS Citation Index
Chemical Abstracts
Current Contents - Life Sciences
Embase
Environmental Mutagene Information Center
Elsevier BIOBASE
PubMed/Medline
Scopus
Cambridge Scientific Abstracts

EDITORIAL BOARD

*Editor-in-Chief*
Mathieu Vinken, Vrije Universiteit Brussel, Department of In Vitro Toxicology, Laarbeeklaan 103, 1090, Brussels, Belgium

*Associate Editors*
Emanuela Corsini, University of Milan, Department of Environmental Science and Policy, Milano, Italy
Thomas Knudsen, US Environmental Protection Agency Center for Computational Toxicology and Exposure, Research Triangle Park, North Carolina, United States of America
Christopher Lau, United States Environmental Protection Agency, Washington, District of Columbia, United States of America
Nan Sang, Shanxi University, College of Environment and Resource, Research Center of Environment and Health, Taiyuan, China
Matthew Wright, Newcastle University Translational and Clinical Research Institute, Newcastle upon Tyne, United Kingdom

*Emeritus Editor*
Kendall B. Wallace, University of Minnesota Medical School, Department of Biochemistry Molecular Biology and Biophysics, Duluth, Minnesota, United States of America

*Editorial Board*
Stelvio Bandiera, University of Guelph, Department of Chemistry, Guelph, Ontario, Canada
Chemical and biochemical aspects of drug metabolism, Medicinal chemistry, including structure-activity relationships of various classes of drugs, Biochemical aspects of toxicology.
Holger Barth, Ulm University Medical Center Institute of Pharmacology and Toxicology, Ulm, Germany
Bacterial protein toxins, their interaction with mammalian cells and their membrane transport inside cells.
Richard J. Bull, MoBull Consulting, Richland, Washington, United States of America
Jason R. Cannon, Purdue University School of Health Sciences, West Lafayette, Indiana, United States of America
Heterocyclic amines; pesticides; neurodegenerative diseases; neurobehavior; neuropathology; neurotransmission
Gary Carlson, Purdue University School of Health Sciences, West Lafayette, Indiana, United States of America
Omar Cauli, University of Valencia, Department of Nursing, Valencia, Spain
Medicine, Neurology, Geriatrics, Pharmacology
Janice Chambers, Mississippi State University College of Veterinary Medicine, University, Mississippi, United States of America
Men-Chi Chang, Chang Gung University, Taoyuan, Taiwan
Samuel M. Cohen, University of Nebraska Medical Center, Department of Pathology and Microbiology, Omaha, Nebraska, United States of America
Chemical Carcinogenesis, Toxicology and Risk Assessment, Surgical Pathology, Urologic Pathology
Christopher Corton, Environmental Protection Agency Division of Integrated Systems Toxicology, Research Triangle Park, North Carolina, United States of America
Liver Toxicity, Predicting life stage susceptibility and the use of toxicogenomics to predict mode of action and human relevance.

Piyali Dasgupta, Marshall University, Huntington, West Virginia, United States of America
Liver cancer, phytochemicals, signaling, nicotine, drug discovery

George DaSton, The Procter & Gamble Company, Cincinnati, Ohio, United States of America
Pharmacogenomics, Toxicogenomics, developmental toxicology

Javier Del Pino, Complutense University of Madrid, Faculty of Pharmacy, Madrid, Spain
Neurotoxicity, Endocrine disruption, Development, Drugs, metals, Pesticides, Food ingredients, Safety

Jacques Descotes, Regional Centre for Pharmaceutical Surveillance Lyon, Lyon, France

Marion Ehrich, Virginia-Maryland College of Veterinary Medicine, Blacksburg, Virginia, United States of America
General toxicology, General pharmacology, Neurotoxic esterase, Organophosphate toxicity, Organophosphate-induced delayed neuropathy

Janine Ezendam, National Institute for Public Health and the Environment, Bilthoven, Netherlands

John R. Foster, Regulatory Science Associates Pathology Group, Congleton, United Kingdom
Toxicology, Pathology, Carcinogenesis, Regulatory, Research

Robert M. Gogal, University of Georgia, Athens, Georgia, United States of America
Clinical Immunology, Immunotoxicology, Cancer Immunology

Mary Gulumian, National Institute for Occupational Health, Johannesburg, South Africa

Stefan Hockertz, Baar, Switzerland

Zhenlie Huang, Southern Medical University, Guangzhou, Guangdong, China

Jan Ji, Shanghai Medicon Inc, Shanghai, China
Toxicity, Molecular biology, (sc)RNA-sequencing, Bioinformatics, Pathology, Tissue Engineering

Milan Jokanovic, Serbian Academy of Sciences and Arts, Beograd, Serbia

Norbert Kaminski, Michigan State University, Department of Pharmacology and Toxicology, East Lansing, Michigan, United States of America

Wilma Kempinas, São Paulo State University Institute of Biosciences, Botucatu, Brazil
Reproductive toxicology, Developmental toxicology, Reproductive and Developmental Biology

Elaina Kenyon, US Environmental Protection Agency National Health and Environmental Effects Research Laboratory, Research Triangle Park, North Carolina, United States of America
Toxicokinetics, ADME, Physiological Pharmacokinetic Modeling, PBPK, Metals, Disinfection By Products, Pediatric Pharmacokinetics, General Toxicology

M. Firoze Khan, The University of Texas Medical Branch at Galveston, Department of Pathology, Galveston, TX, United States of America
Oxidative stress, Immunotoxicology (autoimmunity) Cardiovascular toxicology, Hematopoietic toxicity Biomarkers, Immunotoxicology, Oxidative stress, autoimmunity

James Klaunig, Indiana University, Department of Pharmacology and Toxicology, Indianapolis, Indiana, United States of America

B. Paige Lawrence, University of Rochester School of Medicine and Dentistry, Rochester, New York, United States of America
Immunotoxicology, Immunology, Infectious disease, Developmental origins of health, Stem and progenitor cells, Epigenetics, Aryl hydrocarbon receptor, Mixtures

Maxwell C. K. Leung, Arizona State University New College of Interdisciplinary Arts and Sciences, Phoenix, Arizona, United States of America

Guoliang Li, Shaanxi University of Science and Technology, Xi’an, China
Nanotoxicology, Nanomaterials, Sensors, Food safety, Emerging pollutants, Regulatory toxicology, Sample pretreatment, Analytical toxicology, food safety

José E. Manautou, University of Connecticut, Department of Pharmaceutical Sciences, Storrs, Connecticut, United States of America
Hepatotoxicity, Model hepatotoxicants (e.g. acetaminophen, carbon tetrachloride), Hepatobiliary disposition of xenobiotics, Hepatoprotection Peroxisome proliferators, Transport proteins, Covalent binding in hepatotoxicity, Reactive intermediates in hepatotoxicity

Richard Manderville, University of Guelph, Guelph, Ontario, Canada

Francis L. Martin, Lancaster University, Department of Biological Sciences, Lancaster, United Kingdom

Edmund Maser, University of Kiel Institute of Toxicology and Pharmacology for Natural Scientists, Kiel, Germany
Special interests: Reductive Drug Metabolism, Carboxyl Reductase; hydroxysteroid dehydrogenases, dihydriodiol dehydrogenase; aldehyde reductase; aldose reductase; reductive enzymes

David McCormick, IIT Research Institute, Chicago, Illinois, United States of America
Toxicology. Pharmacology, Preclinical Drug Development

**Pasquale Mosesso**, University of Tuscia, Department of Biological and Ecological Sciences, Viterbo, Italy
Genetic toxicology, oxidative stress, phototoxicity, skin sensitization, carcinogenicity, radiobiology, chemical mutagenesis

**David Nikolic-Paterson**, Monash University, Department of Medicine, Clayton, Victoria, Australia

**Gunter Oberdörster**, University of Rochester Medical Center, Department of Environmental Medicine, Rochester, New York, United States of America

**Elena A. Ostrakhovitch**, Buck Institute for Research on Aging, Novato, California, United States of America
Metal homeostasis, Redox regulation, Redox signaling, Metal-related signaling, Metabolomics, Metallomics, Aging, Age-associated disorders, Neurodegeneration, Cancer

**Jurgen Pauluhn**, Bayer HealthCare AG Pharma und Chemiepark Wuppertal, Wuppertal, Germany

**Stephane Pillet**, INRS Armand-Frappier Santé Biotechnologie Research Centre, Laval, Quebec, Canada

**Carey Nat Pope**, Oklahoma State University College of Veterinary Medicine, Stillwater, Oklahoma, United States of America
Organophosphates, Peripheral nerve degeneration, Receptor function, General neurotoxicology

**Gary O. Rankin**, Marshall University, Department of Biomedical Sciences, Huntington, West Virginia, United States of America

**Cynthia R. Rider**, National Institutes of Health, Bethesda, Maryland, United States of America

**Ivonne Rietjens**, Wageningen University & Research Division of Toxicology, Wageningen, Netherlands
Molecular Enzymology, Biotransformation of Xenobiotics, Computer Modeling (QM and MM), Redox Enzymes, Biochemical Toxicology, Antioxidants

**John Rogers**, US Environmental Protection Agency National Health and Environmental Effects Research Laboratory, Research Triangle Park, North Carolina, United States of America

**Kai Markus Savolainen**, Finnish Institute of Occupational Health, HELSINKI, Finland
Nanotoxicology, genotoxicology, immunotoxicology, nanosafety, nanomaterials, risk assessment, regulatory toxicology, pharmacology, oxidative stress

**Gilbert Schoenfelder**, Charite University Hospital Berlin Institute of Clinical Pharmacology and Toxicology, Berlin, Germany

**Dieter Schrenk**, TU Kaiserslautern Subject Group Food Chemistry and Toxicology, Kaiserslautern, Germany
Toxicology, chemical carcinogenesis, risk assessment

**David Wallace**, Oklahoma State University Center for Health Sciences, Tulsa, Oklahoma, United States of America
Apoptotic pathways, Energy utilization, Environmental toxicology, Heavy metals, Mitochondrial toxicity, Mixtures, Neurodegeneration, Neurodevelopment, Oxidative stress, Pesticides

**Chiho Watanabe**, Nagasaki University School of Tropical Medicine and Global Health, Nagasaki, Japan
Human Ecology, Planetary Health, Sustainability, Environmental Health, Toxicology

**Calvin C. Willhite**, Risk Sciences International, Ottawa, Ontario, Canada
Developmental toxicology Occupational health Human health risk assessment Reproductive toxicology

**Di Wu**, Queen’s University Belfast Institute for Global Food Security, Belfast, United Kingdom
Food Integrity, Food Chemistry, Mass Spectrometry, AI and Machine Learning, Food Allergy, Alternative Protein, Spectroscopy, Metabolism

**Honorary Editors**

**Hans Marquardt**, Hamburg University Medical School, Department of Toxicology, Kortenredder 3, 22397, Hamburg, Germany, Fax: +49 40 60558553

**Karl Netter**, University of Marburg Institute of Pharmacology and Clinical Pharmacy, Karl-von-Frisch-Strasse 1, 35043, Marburg, Germany, Fax: +49 6421 2865600

**Hans-Peter Witsch**i, University of California Davis Center for Health and the Environment, Old Davis Road, Building 3792, Room 129, CA 95616-8615, Davis, California, United States of America, Fax: +1 530 752 5300
**GUIDE FOR AUTHORS**

**INTRODUCTION**

*Toxicology*, an international journal, publishes only the highest quality original research and critical reviews dealing with the adverse effects of xenobiotics on the health of humans and animals. The goal of the journal is to advance the scientific understanding of mechanisms of toxicity. Emphasis will be placed on toxic effects observed at relevant exposures, which have direct impact on safety evaluation and risk assessment. All manuscripts published in *Toxicology* are subject to rigorous peer review.

**Types of paper**

In addition to original research articles, concise and current review and mini-review articles are also welcome, as are personal opinion papers and commentaries. Please consult the Managing Editors for special instructions prior to submitting such articles.

**Submission checklist**

You can use this list to carry out a final check of your submission before you send it to the journal for review. Please check the relevant section in this Guide for Authors for more details.

Ensure that the following items are present:

One author has been designated as the corresponding author with contact details:

- E-mail address
- Full postal address

All necessary files have been uploaded:

*Manuscript*:
- Include keywords
- All figures (include relevant captions)
- All tables (including titles, description, footnotes)
- Ensure all figure and table citations in the text match the files provided
- Indicate clearly if color should be used for any figures in print

*Graphical Abstracts / Highlights files* (where applicable)

*Supplemental files* (where applicable)

Further considerations:

- Manuscript has been 'spell checked' and 'grammar checked'
- All references mentioned in the Reference List are cited in the text, and vice versa
- Permission has been obtained for use of copyrighted material from other sources (including the Internet)
- A competing interests statement is provided, even if the authors have no competing interests to declare
- Journal policies detailed in this guide have been reviewed
- Referee suggestions and contact details provided, based on journal requirements

For further information, visit our Support Center.

**BEFORE YOU BEGIN**

**Ethics in publishing**

Please see our information on Ethics in publishing.

**Studies in humans and animals**

If the work involves the use of human subjects, the author should ensure that the work described has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans. The manuscript should be in line with the Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals and aim for the inclusion of representative human populations (sex, age and ethnicity) as per those recommendations. The terms sex and gender should be used correctly.

Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed.
All animal experiments should comply with the ARRIVE guidelines and should be carried out in accordance with the U.K. Animals (Scientific Procedures) Act, 1986 and associated guidelines, EU Directive 2010/63/EU for animal experiments, or the National Research Council’s Guide for the Care and Use of Laboratory Animals and the authors should clearly indicate in the manuscript that such guidelines have been followed. The sex of animals must be indicated, and where appropriate, the influence (or association) of sex on the results of the study.

**Declaration of competing interest**

Corresponding authors, on behalf of all the authors of a submission, must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. All authors, including those without competing interests to declare, should provide the relevant information to the corresponding author (which, where relevant, may specify they have nothing to declare). Corresponding authors should then use this tool to create a shared statement and upload to the submission system at the Attach Files step. Please do not convert the .docx template to another file type. Author signatures are not required.

**Declaration of generative AI in scientific writing**

The below guidance only refers to the writing process, and not to the use of AI tools to analyse and draw insights from data as part of the research process.

Where authors use generative artificial intelligence (AI) and AI-assisted technologies in the writing process, authors should only use these technologies to improve readability and language. Applying the technology should be done with human oversight and control, and authors should carefully review and edit the result, as AI can generate authoritative-sounding output that can be incorrect, incomplete or biased. AI and AI-assisted technologies should not be listed as an author or co-author, or be cited as an author. Authorship implies responsibilities and tasks that can only be attributed to and performed by humans, as outlined in Elsevier’s AI policy for authors.

Authors should disclose in their manuscript the use of AI and AI-assisted technologies in the writing process by following the instructions below. A statement will appear in the published work. Please note that authors are ultimately responsible and accountable for the contents of the work.

**Disclosure instructions**

Authors must disclose the use of generative AI and AI-assisted technologies in the writing process by adding a statement at the end of their manuscript in the core manuscript file, before the References list. The statement should be placed in a new section entitled ‘Declaration of Generative AI and AI-assisted technologies in the writing process’.

Statement: During the preparation of this work the author(s) used [NAME TOOL / SERVICE] in order to [REASON]. After using this tool/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the publication.

This declaration does not apply to the use of basic tools for checking grammar, spelling, references etc. If there is nothing to disclose, there is no need to add a statement.

**Submission declaration**

Submission of an article implies that the work described has not been published previously (except in the form of an abstract, a published lecture or academic thesis, see ‘Multiple, redundant or concurrent publication’ for more information), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder.

**Submission declaration and verification**

Submission of an article implies that the work described has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis or as an electronic preprint, see https://www.elsevier.com/postingpolicy), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published.
elsewhere in the same form, in English or in any other language, including electronically without
the written consent of the copyright-holder. To verify originality, your article may be checked by the
originality detection service CrossCheck https://www.elsevier.com/editors/plagdetect.

Furthermore, it is understood that with submission of this article the authors have complied with the
institutional policies governing the humane and ethical treatment of the experimental subjects, and
that they are willing to share the original data and materials if so requested.

**Preprints**
Please note that preprints can be shared anywhere at any time, in line with Elsevier's sharing policy.
Sharing your preprints e.g. on a preprint server will not count as prior publication (see ‘Multiple,
redundant or concurrent publication’ for more information).

**Use of inclusive language**
Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences,
and promotes equal opportunities. Content should make no assumptions about the beliefs or
commitments of any reader; contain nothing which might imply that one individual is superior to
another on the grounds of age, gender, race, ethnicity, culture, sexual orientation, disability or health
condition; and use inclusive language throughout. Authors should ensure that writing is free from bias,
stereotypes, slang, reference to dominant culture and/or cultural assumptions. We advise to seek
gender neutrality by using plural nouns (“clinicians, patients/clients”) as default/wherever possible
to avoid using "he, she," or "he/she." We recommend avoiding the use of descriptors that refer
to personal attributes such as age, gender, race, ethnicity, culture, sexual orientation, disability or health
condition unless they are relevant and valid. When coding terminology is used, we recommend
to avoid offensive or exclusionary terms such as "master", "slave", "blacklist" and "whitelist". We
suggest using alternatives that are more appropriate and (self-) explanatory such as "primary",
"secondary", "blocklist" and "allowlist". These guidelines are meant as a point of reference to help
identify appropriate language but are by no means exhaustive or definitive.

**Reporting sex- and gender-based analyses**

**Reporting guidance**
For research involving or pertaining to humans, animals or eukaryotic cells, investigators should
integrate sex and gender-based analyses (SGBA) into their research design according to funder/
sponsor requirements and best practices within a field. Authors should address the sex and/or gender
dimensions of their research in their article. In cases where they cannot, they should discuss this
as a limitation to their research's generalizability. Importantly, authors should explicitly state what
definitions of sex and/or gender they are applying to enhance the precision, rigor and reproducibility
of their research and to avoid ambiguity or conflation of terms and the constructs to which they
refer (see Definitions section below). Authors can refer to the Sex and Gender Equity in Research
(SAGER) guidelines and the SAGER guidelines checklist. These offer systematic approaches to the use
and editorial review of sex and gender information in study design, data analysis, outcome reporting
and research interpretation - however, please note there is no single, universally agreed-upon set of
guidelines for defining sex and gender.

**Definitions**
Sex generally refers to a set of biological attributes that are associated with physical and physiological
features (e.g., chromosomal genotype, hormonal levels, internal and external anatomy). A binary sex
categorization (male/female) is usually designated at birth ("sex assigned at birth"), most often based
solely on the visible external anatomy of a newborn. Gender generally refers to socially constructed
roles, behaviors, and identities of women, men and gender-diverse people that occur in a historical
and cultural context and may vary across societies and over time. Gender influences how people view
themselves and each other, how they behave and interact and how power is distributed in society. Sex
and gender are often incorrectly portrayed as binary (female/male or woman/man) and unchanging
whereas these constructs actually exist along a spectrum and include additional sex categorizations
and gender identities such as people who are intersex/have differences of sex development (DSD) or
identify as non-binary. Moreover, the terms "sex" and "gender" can be ambiguous—thus it is important
for authors to define the manner in which they are used. In addition to this definition guidance and
the SAGER guidelines, the resources on this page offer further insight around sex and gender in
research studies.
Changes to authorship
Authors are expected to consider carefully the list and order of authors before submitting their manuscript and provide the definitive list of authors at the time of the original submission. Any addition, deletion or rearrangement of author names in the authorship list should be made only before the manuscript has been accepted and only if approved by the journal Editor. To request such a change, the Editor must receive the following from the corresponding author: (a) the reason for the change in author list and (b) written confirmation (e-mail, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed.

Only in exceptional circumstances will the Editor consider the addition, deletion or rearrangement of authors after the manuscript has been accepted. While the Editor considers the request, publication of the manuscript will be suspended. If the manuscript has already been published in an online issue, any requests approved by the Editor will result in a corrigendum.

Article transfer service
This journal uses the Elsevier Article Transfer Service to find the best home for your manuscript. This means that if an editor feels your manuscript is more suitable for an alternative journal, you might be asked to consider transferring the manuscript to such a journal. The recommendation might be provided by a Journal Editor, a dedicated Scientific Managing Editor, a tool assisted recommendation, or a combination. If you agree, your manuscript will be transferred, though you will have the opportunity to make changes to the manuscript before the submission is complete. Please note that your manuscript will be independently reviewed by the new journal. More information.

Copyright
Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (see more information on this). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations. If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for use by authors in these cases.

For gold open access articles: Upon acceptance of an article, authors will be asked to complete a 'License Agreement' (more information). Permitted third party reuse of gold open access articles is determined by the author's choice of user license.

Author rights
As an author you (or your employer or institution) have certain rights to reuse your work. More information.

Elsevier supports responsible sharing
Find out how you can share your research published in Elsevier journals.

Role of the funding source
You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement, it is recommended to state this.

Open access
Please visit our Open Access page for more information.

Elsevier Researcher Academy
Researcher Academy is a free e-learning platform designed to support early and mid-career researchers throughout their research journey. The "Learn" environment at Researcher Academy offers several interactive modules, webinars, downloadable guides and resources to guide you through the process of writing for research and going through peer review. Feel free to use these free resources to improve your submission and navigate the publication process with ease.
Language (usage and editing services)
Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the English Language Editing service available from Elsevier's Author Services.

Submission
Submission to this journal proceeds totally online and you will be guided stepwise through the creation and uploading of your files. The system automatically converts source files to a single PDF file of the article, which is used in the peer-review process. Please note that even though manuscript source files are converted to PDF files at submission for the review process, these source files are needed for further processing after acceptance. All correspondence, including notification of the Editor's decision and requests for revision, takes place by e-mail removing the need for a paper trail.
Each manuscript must also be accompanied by a cover letter outlining the basic findings of the paper and their significance. When submitting the revised manuscript, it is a requirement to submit two versions:
Revised Manuscript without tracked changes: The manuscript should be a single word processing file containing the title page, abstract, manuscript text, and any figure/table legends.
Revised Manuscript with tracked changes: This file should be the same as the revised manuscript but it should also display the tracked changes. Switch on 'track changes' in your word processor to display any revisions that were made.
Minimal exceptions will be exercised.

Referees
The Editors welcome suggestions by the authors of the names and addresses of up to five individuals who could expertly review the paper, and who are not from the same institutions as the authors. The Editors, reserve the right to use these or other reviewers.

PREPARATION

Queries
For questions about the editorial process (including the status of manuscripts under review) or for technical support on submissions, please visit our Support Center.

Peer review
This journal operates a single anonymized review process. All contributions will be initially assessed by the editor for suitability for the journal. Papers deemed suitable are then typically sent to a minimum of two independent expert reviewers to assess the scientific quality of the paper. The Editor is responsible for the final decision regarding acceptance or rejection of articles. The Editor's decision is final. Editors are not involved in decisions about papers which they have written themselves or have been written by family members or colleagues or which relate to products or services in which the editor has an interest. Any such submission is subject to all of the journal's usual procedures, with peer review handled independently of the relevant editor and their research groups. More information on types of peer review.

Use of word processing software
It is important that the file be saved in the native format of the word processor used. The text should be in single-column format. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. In particular, do not use the word processor's options to justify text or to hyphenate words. However, do use bold face, italics, subscripts, superscripts etc. When preparing tables, if you are using a table grid, use only one grid for each individual table and not a grid for each row. If no grid is used, use tabs, not spaces, to align columns. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the Guide to Publishing with Elsevier). Note that source files of figures, tables and text graphics will be required whether or not you embed your figures in the text. See also the section on Electronic artwork.
To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' functions of your word processor.

Article structure
Manuscripts should be typewritten double spaced.
Abstract: (1) The dose or concentration of the test substance along with (2) the name of the species, cell culture, or other experimental model system should be stated explicitly in the Abstract.

Methods: In this section a statement should be included about the relevance of the (1) dose or concentration (2) experimental model species or cell type to humans.

Subdivision - numbered sections
Divide your article into clearly defined and numbered sections. Subsections should be numbered 1.1 (then 1.1.1, 1.1.2, ...), 1.2, etc. (the abstract is not included in section numbering). Use this numbering also for internal cross-referencing: do not just refer to 'the text'. Any subsection may be given a brief heading. Each heading should appear on its own separate line.

Introduction
State the objectives of the work and provide an adequate background, avoiding a detailed literature survey or a summary of the results.

Material and methods
Provide sufficient details to allow the work to be reproduced by an independent researcher. Methods that are already published should be summarized, and indicated by a reference. If quoting directly from a previously published method, use quotation marks and also cite the source. Any modifications to existing methods should also be described.

Results
Results should be clear and concise.

Discussion
This should explore the significance of the results of the work, not repeat them. A combined Results and Discussion section is often appropriate. Avoid extensive citations and discussion of published literature.

Conclusions
The main conclusions of the study may be presented in a short Conclusions section, which may stand alone or form a subsection of a Discussion or Results and Discussion section.

Appendices
If there is more than one appendix, they should be identified as A, B, etc. Formulae and equations in appendices should be given separate numbering: Eq. (A.1), Eq. (A.2), etc.; in a subsequent appendix, Eq. (B.1) and so on. Similarly for tables and figures: Table A.1; Fig. A.1, etc.

Essential title page information
• Title. Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.

• Author names and affiliations. Please clearly indicate the given name(s) and family name(s) of each author and check that all names are accurately spelled. You can add your name between parentheses in your own script behind the English transliteration. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author.

• Corresponding author. Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. This responsibility includes answering any future queries about Methodology and Materials. Ensure that the e-mail address is given and that contact details are kept up to date by the corresponding author.

• Present/permanent address. If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

Highlights
Highlights are optional yet highly encouraged for this journal, as they increase the discoverability of your article via search engines. They consist of a short collection of bullet points that capture the novel results of your research as well as new methods that were used during the study (If any). Please have a look at the examples here: example Highlights.
Highlights should be submitted in a separate editable file in the online submission system. Please use 'Highlights' in the file name and include 3 to 5 bullet points (maximum 85 characters, including spaces, per bullet point).

**Abstract**
A concise and factual abstract is required. The abstract should state briefly the purpose of the research, the principal results and major conclusions. An abstract is often presented separately from the article, so it must be able to stand alone. For this reason, References should be avoided, but if essential, then cite the author(s) and year(s). Also, non-standard or uncommon abbreviations should be avoided, but if essential they must be defined at their first mention in the abstract itself.

**Graphical abstract**
Although a graphical abstract is optional, its use is encouraged as it draws more attention to the online article. The graphical abstract should summarize the contents of the article in a concise, pictorial form designed to capture the attention of a wide readership. Graphical abstracts should be submitted as a separate file in the online submission system. Image size: Please provide an image with a minimum of 531 × 1328 pixels (h × w) or proportionally more. The image should be readable at a size of 5 × 13 cm using a regular screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or MS Office files. You can view Example Graphical Abstracts on our information site.

**Keywords**
Immediately after the abstract, provide 3 to maximum 6 keywords that include the full chemical name(s). Use British spelling and avoid general and plural terms and multiple concepts (avoid, for example, "and", "of"). Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords will be used for indexing purposes.

**Abbreviations**
Define abbreviations that are not standard in this field in a footnote to be placed on the first page of the article. Such abbreviations that are unavoidable in the abstract must be defined at their first mention there, as well as in the footnote. Ensure consistency of abbreviations throughout the article.

**Acknowledgements**
Collate acknowledgements in a separate section at the end of the article before the references and do not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proof reading the article, etc.).

**Formatting of funding sources**
List funding sources in this standard way to facilitate compliance to funder's requirements:

Funding: This work was supported by the National Institutes of Health [grant numbers xxxx, yyyy]; the Bill & Melinda Gates Foundation, Seattle, WA [grant number zzzz]; and the United States Institutes of Peace [grant number aaaa].

It is not necessary to include detailed descriptions on the program or type of grants and awards. When funding is from a block grant or other resources available to a university, college, or other research institution, submit the name of the institute or organization that provided the funding.

If no funding has been provided for the research, it is recommended to include the following sentence:

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

**Math formulae**
Please submit math equations as editable text and not as images. Present simple formulae in line with normal text where possible and use the solidus (/) instead of a horizontal line for small fractional terms, e.g., X/Y. In principle, variables are to be presented in italics. Powers of e are often more conveniently denoted by exp. Number consecutively any equations that have to be displayed separately from the text (if referred to explicitly in the text).
Footnotes
Footnotes should be used sparingly. Number them consecutively throughout the article. Many word processors can build footnotes into the text, and this feature may be used. Otherwise, please indicate the position of footnotes in the text and list the footnotes themselves separately at the end of the article. Do not include footnotes in the Reference list.

Artwork
Electronic artwork
General points
• Make sure you use uniform lettering and sizing of your original artwork.
• Embed the used fonts if the application provides that option.
• Aim to use the following fonts in your illustrations: Arial, Courier, Times New Roman, Symbol, or use fonts that look similar.
• Number the illustrations according to their sequence in the text.
• Use a logical naming convention for your artwork files.
• Provide captions to illustrations separately.
• Size the illustrations close to the desired dimensions of the published version.
• Submit each illustration as a separate file.
• Ensure that color images are accessible to all, including those with impaired color vision.

A detailed guide on electronic artwork is available.
You are urged to visit this site; some excerpts from the detailed information are given here.

Formats
If your electronic artwork is created in a Microsoft Office application (Word, PowerPoint, Excel) then please supply 'as is' in the native document format.
Regardless of the application used other than Microsoft Office, when your electronic artwork is finalized, please 'Save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):
EPS (or PDF): Vector drawings, embed all used fonts.
TIFF (or JPEG): Color or grayscale photographs (halftones), keep to a minimum of 300 dpi.
TIFF (or JPEG): Bitmapped (pure black & white pixels) line drawings, keep to a minimum of 1000 dpi.
TIFF (or JPEG): Combinations bitmapped line/halftone (color or grayscale), keep to a minimum of 500 dpi.

Please do not:
• Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); these typically have a low number of pixels and limited set of colors;
• Supply files that are too low in resolution;
• Submit graphics that are disproportionately large for the content.

Color artwork
Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF), or MS Office files) and with the correct resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear in color online (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations are reproduced in color in the printed version. For color reproduction in print, you will receive information regarding the costs from Elsevier after receipt of your accepted article. Please indicate your preference for color: in print or online only. Further information on the preparation of electronic artwork.

Figure captions
Ensure that each illustration has a caption. Supply captions separately, not attached to the figure. A caption should comprise a brief title (not on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

Tables
Please submit tables as editable text and not as images. Tables can be placed either next to the relevant text in the article, or on separate page(s) at the end. Number tables consecutively in accordance with their appearance in the text and place any table notes below the table body. Be sparing in the use of tables and ensure that the data presented in them do not duplicate results described elsewhere in the article. Please avoid using vertical rules and shading in table cells.

References
Citation in text
Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either 'Unpublished results' or 'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted for publication.

Reference links
Increased discoverability of research and high quality peer review are ensured by online links to the sources cited. In order to allow us to create links to abstracting and indexing services, such as Scopus, Crossref and PubMed, please ensure that data provided in the references are correct. Please note that incorrect surnames, journal/book titles, publication year and pagination may prevent link creation. When copying references, please be careful as they may already contain errors. Use of the DOI is highly encouraged.

A DOI is guaranteed never to change, so you can use it as a permanent link to any electronic article. An example of a citation using DOI for an article not yet in an issue is: VanDecar J.C., Russo R.M., James D.E., Ambeh W.B., Franke M. (2003). Aseismic continuation of the Lesser Antilles slab beneath northeastern Venezuela. Journal of Geophysical Research, https://doi.org/10.1029/2001JB000884. Please note the format of such citations should be in the same style as all other references in the paper.

Web references
As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately (e.g., after the reference list) under a different heading if desired, or can be included in the reference list.

Data references
This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them in your text and including a data reference in your Reference List. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add [dataset] immediately before the reference so we can properly identify it as a data reference. The [dataset] identifier will not appear in your published article.

Preprint references
Where a preprint has subsequently become available as a peer-reviewed publication, the formal publication should be used as the reference. If there are preprints that are central to your work or that cover crucial developments in the topic, but are not yet formally published, these may be referenced. Preprints should be clearly marked as such, for example by including the word preprint, or the name of the preprint server, as part of the reference. The preprint DOI should also be provided.

References in a special issue
Please ensure that the words 'this issue' are added to any references in the list (and any citations in the text) to other articles in the same Special Issue.

Reference management software
Most Elsevier journals have their reference template available in many of the most popular reference management software products. These include all products that support Citation Style Language styles, such as Mendeley. Using citation plug-ins from these products, authors only need to select the appropriate journal template when preparing their article, after which citations and bibliographies will be automatically formatted in the journal’s style. If no template is yet available for this journal, please follow the format of the sample references and citations as shown in this Guide. If you use reference management software, please ensure that you remove all field codes before submitting the electronic manuscript. More information on how to remove field codes from different reference management software.

Reference formatting
There are no strict requirements on reference formatting at submission. References can be in any style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book title, chapter title/article title, year of publication, volume number/book chapter and the article number or pagination must be present. Use of DOI is highly encouraged. The reference style used by
the journal will be applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the author to correct. If you do wish to format the references yourself they should be arranged according to the following examples:

Reference style
Text: All citations in the text should refer to:
1. **Single author:** the author's name (without initials, unless there is ambiguity) and the year of publication;
2. **Two authors:** both authors' names and the year of publication;
3. **Three or more authors:** first author's name followed by 'et al.' and the year of publication.

Citations may be made directly (or parenthetically). Groups of references can be listed either first alphabetically, then chronologically, or vice versa.

Examples: 'as demonstrated (Allan, 2000a, 2000b, 1999; Allan and Jones, 1999).... Or, as demonstrated (Jones, 1999; Allan, 2000)... Kramer et al. (2010) have recently shown ...'

List: References should be arranged first alphabetically and then further sorted chronologically if necessary. More than one reference from the same author(s) in the same year must be identified by the letters 'a', 'b', 'c', etc., placed after the year of publication.

Examples:
Reference to a journal publication:

Reference to a journal publication with an article number:

Reference to a book:

Reference to a chapter in an edited book:

Reference to a website:

Reference to a dataset:

Reference to software:

Journal abbreviations source
Journal names should be abbreviated according to the List of Title Word Abbreviations.

Video
Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include links to these within the body of the article. This can be done in the same way as a figure or table by referring to the video or animation content and noting in the body text where it should be placed. All submitted files should be properly labeled so that they directly relate to the video file's content. In order to ensure that your video or animation material is directly usable, please provide the file in one of our recommended file formats with a preferred maximum size of 150 MB per file, 1 GB in total. Video and animation files supplied will be published online in the electronic version of your article in Elsevier Web products, including ScienceDirect. Please supply 'stills' with your files: you can choose any frame from the video or animation or make a separate image. These will be used instead of standard icons and will personalize the link to your video data. For more detailed instructions please visit our video instruction pages. Note: since video and animation cannot be embedded in the print version of the journal, please provide text for both the electronic and the print version for the portions of the article that refer to this content.
**Supplementary material**
Supplementary material such as applications, images and sound clips, can be published with your article to enhance it. Submitted supplementary items are published exactly as they are received (Excel or PowerPoint files will appear as such online). Please submit your material together with the article and supply a concise, descriptive caption for each supplementary file. If you wish to make changes to supplementary material during any stage of the process, please make sure to provide an updated file. Do not annotate any corrections on a previous version. Please switch off the 'Track Changes' option in Microsoft Office files as these will appear in the published version.

**Research data**
This journal requires and enables you to share data that supports your research publication where appropriate, and enables you to interlink the data with your published articles. Research data refers to the results of observations or experimentation that validate research findings, which may also include software, code, models, algorithms, protocols, methods and other useful materials related to the project.

Below are a number of ways in which you can associate data with your article or make a statement about the availability of your data when submitting your manuscript. When sharing data in one of these ways, you are expected to cite the data in your manuscript and reference list. Please refer to the "References" section for more information about data citation. For more information on depositing, sharing and using research data and other relevant research materials, visit the [research data page](#).

**Research Elements**
This journal enables you to publish research objects related to your original research – such as data, methods, protocols, software and hardware – as an additional paper in a Research Elements journal.

Research Elements is a suite of peer-reviewed, open access journals which make your research objects findable, accessible and reusable. Articles place research objects into context by providing detailed descriptions of objects and their application, and linking to the associated original research articles. Research Elements articles can be prepared by you, or by one of your collaborators.

During submission, you will be alerted to the opportunity to prepare and submit a manuscript to one of the Research Elements journals.

More information can be found on the [Research Elements page](#).

**Data statement**
To foster transparency, we require you to state the availability of your data in your submission if your data is unavailable to access or unsuitable to post. This may also be a requirement of your funding body or institution. You will have the opportunity to provide a data statement during the submission process. The statement will appear with your published article on ScienceDirect. For more information, visit the [Data Statement page](#).

**AFTER ACCEPTANCE**

**Online proof correction**
To ensure a fast publication process of the article, we kindly ask authors to provide us with their proof corrections within two days. Corresponding authors will receive an e-mail with a link to our online proofing system, allowing annotation and correction of proofs online. The environment is similar to MS Word: in addition to editing text, you can also comment on figures/tables and answer questions from the Copy Editor. Web-based proofing provides a faster and less error-prone process by allowing you to directly type your corrections, eliminating the potential introduction of errors.

If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the e-mail we send to authors, including alternative methods to the online version and PDF.

We will do everything possible to get your article published quickly and accurately. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. It is important to ensure that all corrections are sent back to us in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility.
**Offprints**
The corresponding author will, at no cost, receive a customized Share Link providing 50 days free access to the final published version of the article on ScienceDirect. The Share Link can be used for sharing the article via any communication channel, including email and social media. For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication. Corresponding authors who have published their article gold open access do not receive a Share Link as their final published version of the article is available open access on ScienceDirect and can be shared through the article DOI link.

**AUTHOR INQUIRIES**
Visit the Elsevier Support Center to find the answers you need. Here you will find everything from Frequently Asked Questions to ways to get in touch. You can also check the status of your submitted article or find out when your accepted article will be published.

© Copyright 2018 Elsevier | https://www.elsevier.com